Leadership Vacuum: States Pass the Buck on Opioid Settlement Oversight

More than three years after the first major opioid settlements began distributing billions of dollars to state and local governments, a troubling pattern has emerged: nobody is quite sure who's in charge of making sure the money gets spent as promised. A new investigation by KFF Health News reveals a systemic leadership vacuum across multiple states, with agencies pointing fingers at one another while oversight remains fragmented or absent entirely.

The findings carry particular weight as communities devastated by the opioid crisis watch settlement funds accumulate in government accounts. With over $50 billion expected to flow to states through various settlements over the next decade and a half, the question of accountability has shifted from academic concern to urgent practical necessity.

The Accountability Gap

In New York, the investigation found a typical pattern of bureaucratic diffusion. The state's Office of Addiction Services and Supports (OASAS) administers grants funded by settlement dollars. The Office of the State Comptroller conducts financial audits. The Opioid Settlement Fund Advisory Board makes recommendations. But when asked who bears ultimate responsibility for ensuring funds reach evidence-based programs that actually reduce overdose deaths, officials at each entity directed questions elsewhere.

The state comptroller's office confirmed it is conducting an audit of OASAS oversight that began in February, examining how the agency monitors settlement spending. But auditing oversight is not the same as ensuring effective use, and the audit's scope does not extend to whether programs funded are achieving their intended outcomes.

This pattern repeats across state lines. In some jurisdictions, settlement funds flow through attorneys general offices that negotiated the deals but lack public health expertise. In others, health departments control disbursement but face political pressure to direct funds toward law enforcement or other priorities. Local governments often receive direct allocations with minimal strings attached and varying capacity to manage them effectively.

Why Oversight Matters Now

The timing of this accountability gap could hardly be worse. Overdose deaths, while declining from peak levels, remain catastrophically high. The drug supply continues evolving with new synthetic threats. And communities most affected by the crisis—often rural, under-resourced, and politically marginalized—need sustained investment in treatment, harm reduction, and recovery support services.

Opioid addiction treatment programs across the country report waiting lists, workforce shortages, and funding instability. Medication-assisted treatment, the gold standard for opioid use disorder, remains inaccessible in vast swaths of the country. Harm reduction services like syringe exchanges and naloxone distribution programs operate on shoestring budgets even as they demonstrably save lives.

Settlement funds represent a once-in-a-generation opportunity to address these gaps. But without robust oversight, dollars risk being diverted to pet projects, absorbed by administrative costs, or spent on programs lacking evidence of effectiveness. Early reports from some jurisdictions suggest these fears are not hypothetical: funds have gone to police equipment, general budget shortfalls, and programs with tenuous connections to overdose prevention.

Model Legislation and Emerging Solutions

The Reason Foundation, a libertarian think tank, released a model law earlier this year that would create audit requirements for organizations receiving settlement cash. The blueprint suggests recipients of more than $1 million undergo independent review of financial statements and transaction testing to determine whether funds were used for intended purposes. No state has yet adopted the model, though New York's comptroller audit moves partially in this direction.

Some states have developed more promising approaches. Maryland's comprehensive dashboard tracks settlement spending across multiple funds with public-facing transparency. Local jurisdictions in several states have created community advisory boards with lived experience representation to guide allocation decisions. And advocacy organizations increasingly monitor spending and publicize concerns.

But these remain exceptions. The KFF Health News investigation found that even basic transparency—public reporting on how much has been received and spent, on what categories of programs, with what outcomes—is lacking in many jurisdictions. Without this baseline information, meaningful accountability is impossible.

The Federal Role

The settlement agreements themselves, negotiated primarily between state attorneys general and pharmaceutical companies, established few binding requirements for how funds would be managed. This was intentional: negotiators wanted flexibility for local decision-making rather than top-down mandates. But the resulting patchwork has created accountability gaps that may require federal attention.

Congress has held hearings on settlement spending, and some members have proposed legislation requiring greater transparency. The Government Accountability Office has begun examining how selected states are using funds. But meaningful federal oversight would face significant political and legal obstacles, including states' traditional autonomy in criminal justice and public health spending.

The Biden administration has emphasized evidence-based approaches to the opioid crisis through the Office of National Drug Control Policy and SAMHSA. But the administration's influence over settlement funds is limited by the agreements' structure. Technical assistance and best practice guidance are available to interested states, but uptake is voluntary.

What Communities Can Do

For advocates and affected communities, the oversight vacuum creates both challenges and opportunities. Without clear chains of accountability, pushing for transparency requires identifying which officials have leverage and applying pressure accordingly. This might mean testifying at legislative hearings, filing public records requests, organizing media coverage, or supporting candidates who prioritize evidence-based spending.

Several successful models have emerged from grassroots advocacy. In some jurisdictions, community coalitions have secured seats on advisory boards. In others, investigative journalism has exposed problematic spending and prompted reforms. The KFF Health News investigation itself represents the kind of sustained media attention that can catalyze accountability.

The investigation's timing—published as many states enter new fiscal years and budget cycles—creates a window for advocates to push for structural reforms. Requiring public dashboards, independent audits, community representation on decision-making bodies, and outcome reporting could be incorporated into budget legislation or administrative rules.

Looking Forward

The opioid settlement funds represent both an unprecedented resource and a profound test of governmental capacity. Can public institutions, often criticized for inefficiency and inertia, deploy billions of dollars effectively to address one of the most complex public health crises in American history? The early returns, as documented by KFF Health News, suggest reason for concern.

Yet the story is not entirely negative. Some jurisdictions are spending funds thoughtfully on treatment expansion, harm reduction, and recovery support. The settlements have brought new attention to the opioid crisis and new resources to address it. And the very fact of investigative reporting on oversight gaps creates pressure for improvement.

The coming years will determine whether settlement funds become a model for how society responds to corporate-caused public health disasters—or a cautionary tale about missed opportunities and squandered resources. The difference will depend significantly on whether states can overcome the leadership vacuum and establish genuine accountability for how these billions are spent.

For families who lost loved ones to overdose, for communities still struggling with addiction's devastation, and for treatment providers working with inadequate resources, the stakes could not be higher. The money is finally flowing. Whether it flows to programs that save lives remains an open question.